Dr. Peter Fecci, MD

• Neurosurgery

• Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Dana Farber Cancer Int

  Fellowship Hospital, 2012

• Massachusetts General Hospital

  Internship Hospital, 2008

• Duke University

  Medical School, 2007

• Duke University School Of Medicine

  Medical School, 2007

• Cornell University

  Undergraduate School, 1999

• Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies, 2021-11-18

• Operative and peri-operative considerations in the management of brain metastasis, 2019-09-30

• Brain immunology and immunotherapy in brain tumours, 2019-12-05

• The Safety of Available Immunotherapy for the Treatment of Glioblastoma, 2017-01-03

• Dendritic cells enhance polyfunctionality of adoptively transferred T cells which targetcytomegalovirusin glioblastoma, 2017-11-01

• Checkpoint inhibition and CAR T cells for the Treatment of Glioblastoma, 2020-02-17

• Sequestration of T-cells in bone marrow in the setting of glioblastoma and other intracranial tumors, 2018-08-13

• Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome, 2021-02-04

• Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, 2016-02-17

• Editorial: It takes a village: The expanding multi-disciplinary approach to brain metastasis, 2022-10-19

• T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma, 2018-02-07

• 4-1BB Agonism as a strategy to license immune checkpoint blockade in glioblastoma, 2020-05-14

• Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage, 2014-06-18

• Flow Cytometric Identification of Tumor-Infiltrating Lymphocytes from Glioblastoma, 2019-10-18

• CD4 T-cell exhaustion: Does it exist and what are its roles in cancer?, 2021-06-14

• CD8+T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis, 2023-08-03

• Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy, 2018-06-11

• Checkpoint blockade therapy for functioning pituitary adenomas, 2020-06-01

• Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege, 2014-11-15

• Navigating the ventricles: Novel insights into the pathogenesis of hydrocephalus, 2022-03-17

• Immune suppression in gliomas, 2020-06-15

• Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors, 2013-09-27

• Prospect of rindopepimut in the treatment of glioblastoma, 2017-03-05

• Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease, 2019-11-19

• T-cell Dysfunction in Glioblastoma: Applying a New Framework, 2018-03-28

• Preventing Lck activation in CAR T cells confers Treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in non-lymphodepleted hosts, 2018-11-13

• 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers, 2019-12-23

• The Evolving Modern Management of Brain Metastasis, 2019-06-18

• Regulatory T cells move in when gliomas say "I-DO”, 2012-10-10

• Laser interstitial thermal therapy for brain metastases, 2021-11-27

• Salting the soil: Targeting the microenvironment of brain metastases, 2021-01-05

• Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma, 2022-10-29

• Leptomeningeal disease: current diagnostic and therapeutic strategies, 2017-08-16

• Antibody-based immunotherapy for malignant glioma, 2014-06-12

• STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment, 2016-02-01

• A Need for More Molecular Profiling in Brain Metastases, 2022-01-25

• Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors, 2016-09-17